目的 研究2014—2016年5-氨基水楊酸類藥物在武漢地區(qū)的應(yīng)用情況和發(fā)展趨勢，為臨床合理用藥提供參考。方法 采用世界衛(wèi)生組織推薦的限定日劑量（DDD）為指標(biāo)的分析方法，對武漢地區(qū)31家醫(yī)院2014-2016年5-氨基水楊酸類藥物的銷售金額、用藥頻度（DDDs）、限定日費用（DDC）、排序比（B/A）等進(jìn)行統(tǒng)計分析。結(jié)果 武漢地區(qū)2014—2016年5-氨基水楊酸類藥物的銷售總金額呈逐年上升趨勢。美沙拉嗪的銷售金額和DDDs均高居第1位，柳氮磺吡啶的銷售金額和DDDs均以較大的差距位居第2位，巴柳氮和奧沙拉嗪的應(yīng)用非常少。美沙拉嗪和柳氮磺吡啶的B/A均為1.00。結(jié)論 2014—2016年5-氨基水楊酸類藥物的臨床應(yīng)用逐年增加，但是臨床應(yīng)用品種單一，主要以美沙拉嗪占據(jù)市場，且以緩釋制劑應(yīng)用最多，因此我國仍需加強對于治療潰瘍性結(jié)腸炎藥物的研發(fā)。

Objective To analyze the application status of 5-aminosalicylic acids of 31 hospitals in Wuhan area from 2014 to 2016, and to provide references for rational clinical use of these drugs. Methods The total consumption sum, DDDs, and the sequenced ratio of 5-aminosalicylic acid applied in 31 hospitals in Wuhan area from 2014 to 2016 were analyzed statistically using the analytical method of the defined daily dose (DDD). Results Total consumption sum of 5-aminosalicylic acid in Wuhan area increased from 2014 to 2016. Consumption sum and DDDs of mesalazine ranked at the first place, followed by sulfasalazine with a significant gap, while Balsalazide and Olsalazine ranked at the bottom. B/A of mesalazine and sulfasalazine were both stabilized at 1.00. Conclusion The clinical utilization of 5-aminosalicylic acids increase year by year from 2014 to 2016, but the application varieties are single, and mesalazine has already occupied the market with sustained release preparation used mainly. Therefore, the research of drugs in treatment of ulcerative colitis need be strengthened in China.